1MARGREITER R, POHANKA E, SPARACINO V, et al. Open prospective multicenter study of conversion to tacrnlimus therapy in renal transplant patients experiencing ciclosporin-related side-effects [ J ]. Transplant Int, 2005, 18(7) :816-823.
2KRHENBU H L,STEPHA N, MENAFOGL I O, et al. Seri- ons interaction between mibefradil and tacrolimus [ J ]. Transplantation, 1998,66 (8) : 1113-1115.
3FERRARESSO M, TIRELLI A, GHIO L, et al. Influence of the CYP3A5 genotype on tacrolimus pharmacokinetics and pharmacodynamics in young kidney transplant recipients [ J ]. Pediatr Transplant,2007,11 ( 3 ) : 296-300.
4YANO I. Pharmacodynamic monitoring of calcineurin phos- phatase activity in transplant patients treated with calcineurin inhibitors [ J ]. Drug Metab Pharmaeokinet, 2008,23(3) : 150-157.
5LEE R A, GABARDI S. Current trends in immunosup- pressive therapies for renal transplant recipients[J]. Am J Health System Pharm ,2012,69 (22) : 1961 - 1975.
